AU2001238346A1 - Modification of biopolymers for improved drug delivery - Google Patents

Modification of biopolymers for improved drug delivery

Info

Publication number
AU2001238346A1
AU2001238346A1 AU2001238346A AU3834601A AU2001238346A1 AU 2001238346 A1 AU2001238346 A1 AU 2001238346A1 AU 2001238346 A AU2001238346 A AU 2001238346A AU 3834601 A AU3834601 A AU 3834601A AU 2001238346 A1 AU2001238346 A1 AU 2001238346A1
Authority
AU
Australia
Prior art keywords
biopolymers
modification
drug delivery
improved drug
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001238346A
Other languages
English (en)
Inventor
Pericles Calias
Robert J. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2001238346A1 publication Critical patent/AU2001238346A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2001238346A 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery Abandoned AU2001238346A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18255800P 2000-02-15 2000-02-15
US60182558 2000-02-15
US21150800P 2000-06-14 2000-06-14
US60211508 2000-06-14
PCT/US2001/004925 WO2001060412A2 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery

Publications (1)

Publication Number Publication Date
AU2001238346A1 true AU2001238346A1 (en) 2001-08-27

Family

ID=26878197

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001238346A Abandoned AU2001238346A1 (en) 2000-02-15 2001-02-15 Modification of biopolymers for improved drug delivery

Country Status (6)

Country Link
EP (1) EP1263472A2 (https=)
JP (1) JP2003522806A (https=)
AU (1) AU2001238346A1 (https=)
CA (1) CA2400205A1 (https=)
IL (1) IL151024A0 (https=)
WO (1) WO2001060412A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
KR20030067755A (ko) * 2001-01-18 2003-08-14 메르크 파텐트 게엠베하 글루코세레브로시다제 활성을 갖는 이관능성 융합 단백질
WO2004060404A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha 薬物担体
WO2005000884A1 (en) * 2003-06-05 2005-01-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
CA2529486A1 (en) * 2003-06-18 2004-12-23 Nst Neurosurvival Technologies Ltd. Method for selective targeting of apoptotic cells and small molecule ligands used thereof
CA2542041C (en) * 2003-10-10 2014-12-09 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
US7625736B2 (en) 2004-06-04 2009-12-01 The United States Of America As Represented By The Department Of Health And Human Services Methods for preparing immunogenic conjugates
TW200612991A (en) 2004-09-07 2006-05-01 Chugai Pharmaceutical Co Ltd Process for producing water-soluble hyaluronic acid modification
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
WO2007008904A2 (en) 2005-07-08 2007-01-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
SI2457920T1 (en) 2007-01-18 2018-02-28 Genzyme Corporation Oligosaccharides containing the amino acid group and their conjugates
CA3040973A1 (en) 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
WO2012118189A1 (ja) 2011-03-03 2012-09-07 中外製薬株式会社 アミノ－カルボン酸により修飾されたヒアルロン酸誘導体
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
JP6275044B2 (ja) 2012-09-05 2018-02-07 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
KR102049568B1 (ko) * 2013-04-01 2019-11-27 삼성전자주식회사 히알루론산을 포함하는 핵산전달용 조성물
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079109A1 (en) * 1990-03-29 1991-09-30 John A. Latham Oligonucleotide-transport agent disulfide conjugates
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
US6335434B1 (en) * 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
US5902795A (en) 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5329029A (en) 1992-11-05 1994-07-12 Wan Barbara Y Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5354853A (en) 1993-03-12 1994-10-11 Genzyme Corporation Phospholipid-saccharide conjugates
IL132941A0 (en) * 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US5932552A (en) 1997-11-26 1999-08-03 Keraplast Technologies Ltd. Keratin-based hydrogel for biomedical applications and method of production

Also Published As

Publication number Publication date
WO2001060412A2 (en) 2001-08-23
WO2001060412A3 (en) 2002-01-24
CA2400205A1 (en) 2001-08-23
IL151024A0 (en) 2003-02-12
EP1263472A2 (en) 2002-12-11
JP2003522806A (ja) 2003-07-29

Similar Documents

Publication Publication Date Title
AU2001235009A1 (en) Drug delivery apparatus
AU2001269529A1 (en) Medicine comprising dicyanopyridine derivative
AU2001264887A1 (en) Drug delivery device
AU2001288388A1 (en) Substance delivery system
PL370889A1 (en) Vaginal delivery of drugs
AU2002217979A1 (en) Medicine feeder
AU2001235691A1 (en) Use of paullone derivatives for making medicines
AU2001238346A1 (en) Modification of biopolymers for improved drug delivery
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2002353444A1 (en) Integrated transdermal drug delivery system
AU2001276860A1 (en) Medicaments for chemotherapeutic treatment of disease
AUPR573001A0 (en) Lymphatic drug delivery system
AU2001277171A1 (en) Catheter for target specific drug delivery
AU6887401A (en) Delivery of remotely-ordered products
AU2001232020A1 (en) Floating drug delivery composition
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
AU2002360717A1 (en) Controlled release dosage form having improved drug release properties
AU2001270963A1 (en) Transdermal drug delivery system
AU2001243515A1 (en) Combination drug therapy
AU2001232244A1 (en) Drug comprising combination
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU3926000A (en) Methods and compositions for drug delivery
AU2002222138A1 (en) Drug delivery system
AU2002212863A1 (en) Stable pharmaceutical form of an anticancer drug